Founded Year



Series B | Alive

Total Raised


Last Raised

$33M | 1 yr ago

About Ultromics

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Ultromics Headquarter Location

4630 Kingsgate Cascade Way

Oxford, England, OX4 2SU,

United Kingdom

ESPs containing Ultromics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Medical Devices Tech

Computer-aided diagnostic imaging utilizes algorithms to detect, extract, and communicate data from medical images more efficiently and accurately than the human eye. The technology is being deployed across several imaging modalities to improve the detection, diagnosis, triaging, and, ultimately, the prognosis of various medical conditions.

Ultromics named as Challenger among 14 other companies, including PathAI, Ibex Medical Analytics, and Aidoc Medical.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ultromics's Products & Differentiation

See Ultromics's products and how their products differentiate from alternatives and competitors

  • EchoGo

    Ultromics’ products operate through the cloud, as a Software-as-a-Service (SaaS) connected with Microsoft Azure cloud. Once connected, starting scanning, and let Ultromics take care of analysis. We’ll provides reports without the need to for any physical software or manual interaction, with results trusted globally by sites including Mayo Clinic, Cleveland Clinic, and the American Society of Echocardiography.

Research containing Ultromics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ultromics in 1 CB Insights research brief, most recently on Jun 18, 2020.

Expert Collections containing Ultromics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ultromics is included in 7 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

11,970 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

10,541 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Latest Ultromics News

Global Cardiovascular Ultrasound Market to Surpass US$ 2,362.24 Million by 2030, Says Coherent Market Insights (CMI)

Jun 9, 2022

Pune, INDIA SEATTLE, June 09, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cardiovascular ultrasound market is estimated to be valued at US$ 1,541.75 Million in 2022 and expected to exhibit a CAGR of 5.5% over the forecast period (2022-2030). Key Trends and Analysis of the Global Cardiovascular Ultrasound Market: Increasing government initiatives to increase awareness about cardiovascular diseases is expected to drive the market growth over the forecast period. In June 2020, the Australian government made an investment of AUD 29 million (US$ 22 million), under the Medical Research Future Fund’s (MRFF) Cardiovascular Health Mission. This was the first round of investment out of the total AUD 220 million (US$ 167 million) allotted for research in the management of cardiovascular diseases to prevent heart attack and stroke, which are the top most causes of death in Australia. Furthermore, key market players are focusing on the adoption of inorganic growth strategies such as acquisition and collaboration in order to expand their product portfolio and presence in the global cardiovascular ultrasound market. For instance, in November 2021, Caption Health, a U.S.-based AI technology developer and Ultromics Limited, a U.K.-based digital health solutions provider, entered into a collaboration to develop artificial intelligence (AI)-based ultrasound analytics in order to accelerate detection and treatment of cardiovascular disease in more accessible care settings of skin care needs, including general dermatology, surgical, pathology, radiation, and cosmetic services. Request Sample copy of this Report @ Key Market Takeaways: The global cardiovascular ultrasound market is expected to exhibit a CAGR of 5.5% during the forecast period, owing to the increasing product launches and approval. For instance, in February 2022, FUJIFILM Sonosite, Inc., a medical ultrasound systems manufacturer, announced launch of its new, premium Sonosite LX system, which features a monitor that extends, rotates, and tilts to accommodate according to the varied clinical environments at the bedside. The clinical display features touchscreen controls to enable an optimized heads-up workflow, allowing clinicians to keep their eyes on the image while making adjustments. Among Modality, portable segment is estimated to account for the largest share in 2022 and is expected to retain its dominance over the forecast period owing to increasing launch of novel portable cardiovascular ultrasound devices, which is expected to drive the segment growth over the forecast period. For instance, in February 2022, Philips, a global leader in health technology, announced that it had expanded its ultrasound portfolio with advanced hemodynamic assessment and measurement capabilities on its handheld point-of-care ultrasound – Lumify. With the addition of Pulse Wave Doppler, it is used in various applications including cardiology, vascular, abdominal, urology, obstetrics, and gynecology. Among End User, hospitals segment is expected to account for a significant share in the global cardiovascular ultrasound market, owing to increasing hospitalizations due to cardiovascular diseases. According to the Heart and Circulatory Disease Statistics 2019 by British Heart Foundation, around 310,885 hospital admissions were reported due to coronary heart disease in the National Health Services (NHS) Hospitals in the U.K. in 2017/18. Competitive Landscape: Key players operating in the global cardiovascular ultrasound market include GE Healthcare (General Electric Company), Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Samsung Medison Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., ESAOTE SPA, and Canon Medical Systems, USA. Buy-Now this Research Report @ Market segmentation: Transthoracic Echocardiogram 2D Portable Hospitals North America

Ultromics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ultromics Rank

  • When was Ultromics founded?

    Ultromics was founded in 2017.

  • Where is Ultromics's headquarters?

    Ultromics's headquarters is located at 4630 Kingsgate, Oxford.

  • What is Ultromics's latest funding round?

    Ultromics's latest funding round is Series B.

  • How much did Ultromics raise?

    Ultromics raised a total of $57.7M.

  • Who are the investors of Ultromics?

    Investors of Ultromics include Oxford Sciences Innovation, Google Ventures, The Blue Venture Fund, Optum Ventures, Mayo Clinic and 11 more.

  • Who are Ultromics's competitors?

    Competitors of Ultromics include Cleerly, Lunit, Aidoc Medical,,, Aidence, SenseTime, Overjet, Iterative Scopes, Aiforia and 40 more.

  • What products does Ultromics offer?

    Ultromics's products include EchoGo.

You May Also Like

Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Infervision Logo

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Koios Medical Logo
Koios Medical

Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics.


Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. Logo aims to use artificial intelligence and deep learning to automatically identify suspected LVOs (large vessel occlusion) on CTA imaging with the aim of alerting a patient's physician within minutes. The company was founded in 2016 and is based in San Francisco, California.

Shukun Technology

Shukun Technology develops diagnostic systems by using machine learning and AI technology for hospitals to improve efficiency. The company focuses on cardiovascular diagnosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.